©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 6 Issue 2 Page 1-5 2025

https://doi.org/10.59298/NIJRMS/2025/6.2.15000

Adjuvants in Infant Immunization: Advances and Challenges in Vaccine Development

Zikayo Amulaga R.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Infant immunization is a cornerstone of global public health, providing protection against life-threatening infectious diseases. However, the immature immune system of infants often results in suboptimal vaccine responses. Adjuvants are critical components of vaccines, enhancing immunogenicity and shaping immune responses to ensure effective and long-lasting protection. This review explores recent advancements in adjuvant technologies, their mechanisms of action, and their role in improving vaccine efficacy in infants. Additionally, we discuss the challenges associated with adjuvant use, including safety concerns, regulatory hurdles, and the need for precision-designed adjuvants that balance efficacy with minimal adverse effects. Ongoing research in novel adjuvant formulations, such as toll-like receptor (TLR) agonists, saponin-based adjuvants, and nanoparticle-based delivery systems, offers promising directions for optimizing infant immunization. Understanding the evolving landscape of adjuvant development is essential for designing next-generation vaccines that provide robust and durable immunity in early life.

Keywords: Infant immunization, Vaccine adjuvants, Immunogenicity enhancement, Novel adjuvant formulations, Next-generation vaccines

INTRODUCTION

Vaccination is one of the most effective strategies for reducing infant morbidity and mortality caused by infectious diseases [1]. However, the neonatal and infant immune system is not fully matured at birth, exhibiting reduced antigen-presenting capacity, lower cytokine production, and weaker T-cell responses compared to older children and adults [2]. These limitations often necessitate multiple vaccine doses or booster immunizations to achieve adequate immunity [3]. Adjuvants—substances added to vaccines to enhance the immune response—play a crucial role in improving vaccine efficacy in infants by promoting stronger and longer-lasting immune protection [4]. The primary function of adjuvants is to enhance antigen presentation, stimulate innate immune pathways, and modulate adaptive immune responses. Traditional adjuvants, such as aluminum salts, have been widely used in infant vaccines for decades, but newer adjuvant formulations aim to elicit more robust and targeted immune responses [5]. Emerging adjuvants, including TLR agonists, MF59 (oil-in-water emulsions), AS01 (liposome-based adjuvants), and nanoparticle-based delivery systems, are being investigated for their potential to improve vaccine efficacy while minimizing reactogenicity [6,7]. This review examines the latest advancements in adjuvant technology for infant vaccines, highlighting their mechanisms of action, safety considerations, and clinical applications. Additionally, we discuss the challenges faced in developing and implementing novel adjuvants, including regulatory requirements, potential adverse effects, and the need for long-term safety studies. Understanding these factors is essential for optimizing vaccine design and ensuring broad and durable immunity in infants.

Mechanisms of Action of Vaccine Adjuvants

Adjuvants are crucial components in vaccine formulations that enhance immune responses by activating innate and adaptive immunity. Their mechanisms of action involve multiple pathways that optimize antigen recognition, immune activation, and memory formation, ensuring robust and long-lasting immunity in infants [6].

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

Enhancing Antigen Presentation

Adjuvants improve the uptake of antigens by antigen-presenting cells (APCs), such as dendritic cells and macrophages, leading to more effective T-cell activation [8]. By forming antigen depots at the injection site, adjuvants facilitate prolonged antigen exposure, allowing APCs to process and present antigens efficiently [9]. This sustained antigen presentation is particularly beneficial in infants, whose immune responses are often weaker and require stronger stimulation to generate effective immunity.

Innate Immune Activation

Many adjuvants stimulate innate immune receptors, such as pattern recognition receptors (PRRs), including toll-like receptors (TLRs) and NOD-like receptors (NLRs) [10]. These receptors recognize pathogen-associated molecular patterns (PAMPs) and activate signaling cascades that lead to the production of pro-inflammatory cytokines and interferons [11]. This activation helps shape adaptive immune responses by enhancing T-cell priming and antibody production, improving the overall effectiveness of vaccines in infants.

Cytokine Modulation

Adjuvants influence the production of pro-inflammatory and regulatory cytokines, promoting balanced immune activation while preventing excessive inflammation [12]. Some adjuvants, such as TLR agonists, enhance the release of interleukins (IL-12, IL-6) and interferons that drive Th1-type immune responses, which are essential for intracellular pathogen defense [13]. Others modulate the cytokine environment to support Th2 or regulatory T-cell responses, ensuring appropriate immune activation without inducing excessive reactogenicity [14].

Antibody Response Enhancement

Certain adjuvants promote stronger B-cell activation and affinity maturation, leading to higher antibody titers and prolonged immune protection [15]. Adjuvants such as aluminum salts enhance humoral immunity by stimulating follicular helper T-cell (Tfh) responses, which aid in the production of high-affinity antibodies [16]. This is particularly crucial in infant immunization, where a strong and durable antibody response is necessary for protection against pathogens like pertussis, diphtheria, and pneumococcus [17].

Traditional and Emerging Adjuvants in Infant Vaccines

1. Aluminum-Based Adjuvants

Aluminum salts (alum) have been used in vaccines for over 90 years and remain among the most widely used adjuvants in infant vaccines. They act by forming antigen depots that prolong immune activation, leading to enhanced antibody production [18]. Alum is particularly effective at inducing strong humoral responses and is used in vaccines against diphtheria, tetanus, and hepatitis B. However, it is less efficient at stimulating cellular immunity, limiting its use in vaccines that require robust T-cell responses [19].

2. Oil-in-Water Emulsions

MF59 (used in influenza vaccines) and AS03 are squalene-based adjuvants that enhance immune responses by recruiting immune cells to the injection site and improving antigen uptake. These adjuvants have been shown to boost antibody production and memory responses, making them promising candidates for pediatric vaccines [20]. Studies indicate that oil-in-water adjuvants improve the immunogenicity of vaccines in young children, helping to overcome immune immaturity.

3. Toll-Like Receptor Agonists

Toll-like receptor (TLR) agonists, such as monophosphoryl lipid A (MPLA, a TLR4 agonist), have been incorporated into novel vaccine formulations to mimic natural infection and stimulate stronger innate immune responses [3, 21]. TLR-based adjuvants enhance antigen presentation, promote Th1-biased immune responses, and improve the efficacy of vaccines against intracellular pathogens [10]. Their ability to enhance both humoral and cellular immunity makes them promising adjuvants for next-generation infant vaccines.

4. Saponin-Based Adjuvants

QS-21, derived from the bark of the Quillaja saponaria tree, is a potent immunostimulant used in AS01-containing vaccines. These adjuvants enhance cellular immunity by activating antigen-presenting cells and promoting robust T-cell responses [9]. Saponin-based adjuvants are currently being explored for use in pediatric vaccines against malaria, tuberculosis, and respiratory viruses. Their ability to stimulate both humoral and cellular immunity makes them valuable candidates for improving vaccine efficacy in infants [22].

5. Nanoparticle-Based Adjuvants

Advancements in nanotechnology have enabled the development of nanoparticle-based vaccine adjuvants that allow precise delivery of antigens and immune stimulants [23]. Liposomes and polymer-based nanoparticles provide controlled antigen release and targeted immune activation, improving vaccine efficacy while minimizing side effects. These adjuvants enhance antigen stability, optimize immune cell interactions, and reduce reactogenicity [24]. Nanoparticle-based adjuvants are being investigated for use in vaccines against respiratory syncytial virus (RSV), pneumococcus, and other early-life infections [25]. Future research continues to explore novel adjuvants that fine-

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

tune immune responses while ensuring safety and minimizing adverse effects in infants. The integration of multiple adjuvant systems, combining innate immune activation with antigen stability and controlled release, holds promise for the next generation of infant vaccines.

Challenges in Adjuvant Development for Infant Vaccines

1. Safety and Reactogenicity

Infants have immature immune systems, making them more susceptible to exaggerated inflammatory responses and potential adverse effects following vaccination. Ensuring the safety of adjuvants is a significant challenge, as excessive immune stimulation can lead to fever, local inflammation, or systemic reactions [26]. While adjuvants enhance immunogenicity, they must be carefully designed to minimize reactogenicity while still providing strong immune protection [4]. Ongoing research focuses on developing precision adjuvants that fine-tune immune responses without triggering excessive inflammation.

2. Regulatory Approval

The introduction of novel adjuvants requires rigorous preclinical and clinical testing to ensure safety and efficacy before regulatory approval. These evaluations involve extensive animal studies, phase I–III human trials, and long-term surveillance to assess potential side effects. The high costs and long timelines associated with regulatory approval present challenges for vaccine manufacturers, delaying the availability of new adjuvanted vaccines for infants. Striking a balance between innovation and regulatory compliance remains a key issue in vaccine development.

3. Efficacy vs. Tolerability Balance

An ideal adjuvant should enhance vaccine-induced immunity without causing excessive reactogenicity [27]. While strong immune activation is necessary to achieve long-lasting protection, overstimulation can lead to local and systemic side effects. Achieving an optimal balance between efficacy and tolerability is particularly crucial in infants, who may be more vulnerable to adverse events [28]. Continuous monitoring of adjuvanted vaccines post-licensure is necessary to assess their long-term safety and effectiveness.

4. Long-Term Immune Programming

The impact of early-life exposure to adjuvants on long-term immune development remains an area of active investigation. Some adjuvants may influence immune programming, affecting susceptibility to infections, allergies, or autoimmune conditions later in life [29]. Understanding how adjuvants shape immune memory and regulatory mechanisms in infancy is essential for optimizing vaccine strategies while minimizing unintended immunological consequences.

Future Directions

Advancements in adjuvant technology continue to drive innovation in infant vaccine development. Researchers are increasingly focused on developing precision adjuvants that can fine-tune immune responses while minimizing reactogenicity [30]. Computational modeling and artificial intelligence are emerging as valuable tools for predicting adjuvant efficacy, optimizing formulations, and reducing the time required for vaccine development. These technologies allow for the rapid screening of novel adjuvants, improving their design and minimizing potential side effects. Combination adjuvant strategies are also gaining attention, where multiple adjuvants with complementary mechanisms are used synergistically to enhance both humoral and cellular immunity [31,32]. This approach can optimize antigen presentation, stimulate innate immune pathways, and promote balanced adaptive immune responses. Novel delivery systems, such as nanoparticle-based and lipid-based adjuvants, are being investigated to improve antigen stability and targeted immune activation. These innovations hold promise for developing vaccines with longer-lasting immunity and broader protection against infectious diseases. Additionally, research is exploring how adjuvants influence immune programming beyond infancy, including their potential role in shaping long-term immune memory and reducing susceptibility to allergies and autoimmune diseases. Understanding these effects will be crucial for designing next-generation adjuvants with maximal benefits and minimal risks.

CONCLUSION

Adjuvants play a crucial role in optimizing infant vaccines by enhancing immune responses and ensuring long-term protection. While traditional adjuvants like aluminum salts have been effective, they have limitations in stimulating cellular immunity. Emerging adjuvant technologies, including toll-like receptor agonists, saponin-based adjuvants, and nanoparticle-based formulations, offer promising solutions for improving vaccine efficacy in early life. However, challenges such as safety concerns, regulatory barriers, and the need for extensive long-term studies must be addressed to ensure their successful implementation. Ongoing research and innovation in adjuvant science will be essential for developing the next generation of infant vaccines, providing enhanced protection against infectious diseases while ensuring safety and efficacy for this vulnerable population.

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

REFERENCES

1. Nandi A, Shet A. Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination. Hum Vaccine Immunotherapy. 2020; 16(8):1900-1904. doi: 10.1080/21645515.2019.1708669. Epub 2020 Jan 24. PMID: 31977283; PMCID: PMC7482790.
2. Lindsey B, Jones C, Kampmann B. Bridging the gap: maternal immunisation as a means to reduce neonatal deaths from infectious diseases. Pathog Glob Health. 2012; 106(3):137-8. doi: 10.1179/204777312X13462106637684. PMID: 23265367; PMCID: PMC4001569.
3. Tesema, G.A., Tessema, Z.T., Tamirat, K.S. *et al.* Complete basic childhood vaccination and associated factors among children aged 12–23 months in East Africa: a multilevel analysis of recent demographic and health surveys. *BMC Public Health* 2020; **20**, 1837. https://doi.org/10.1186/s12889-020-09965-y
4. Facciolà A, Visalli G, Laganà A, Di Pietro A. An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. Vaccines (Basel). 2022; 10(5):819. doi: 10.3390/vaccines10050819. PMID: 35632575; PMCID: PMC9147349.
5. Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, Tian X. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023; 8(1):283. doi: 10.1038/s41392-023-01557-7. PMID: 37468460; PMCID: PMC10356842.
6. Joanna L Turley, Ed C Lavelle. Resolving adjuvant mode of action to enhance vaccine efficacy, Current Opinion in Immunology, 2022; 77, 102229. https://doi.org/10.1016/j.coi.2022.102229.
7. Moni SS, Abdelwahab SI, Jabeen A, Elmobark ME, Aqaili D, Gohal G, Oraibi B, Farasani AM, Jerah AA, Alnajai MMA, et al. Advancements in Vaccine Adjuvants: The Journey from Alum to Nano Formulations. *Vaccines.* 2023; 11(11):1704. https://doi.org/10.3390/vaccines11111704
8. Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013; 4:114. doi: 10.3389/fimmu.2013.00114. PMID: 23720661; PMCID: PMC3655441.
9. Huis in 't Veld, L.G., Cornelissen, L.A., van den Bogaard, L. *et al.* Saponin-based adjuvant uptake and induction of antigen cross-presentation by CD11b+ dendritic cells and macrophages. *npj Vaccines* 2025; **10**, 15. https://doi.org/10.1038/s41541-024-01056-y
10. Wicherska-Pawłowska K, Wróbel T, Rybka J. Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases. Int J Mol Sci. 2021; 22(24):13397. doi: 10.3390/ijms222413397. PMID: 34948194; PMCID: PMC8704656.
11. Li, D., Wu, M. Pattern recognition receptors in health and diseases. *Sig Transduct Target Ther* 2021; **6**, 291. https://doi.org/10.1038/s41392-021-00687-0
12. Al-Qahtani AA, Alhamlan FS, Al-Qahtani AA. Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review. Trop Med Infect Dis. 2024; 9(1):13. doi: 10.3390/tropicalmed9010013. PMID: 38251210; PMCID: PMC10818686.
13. Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, Tian X. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023; 8(1):283. doi: 10.1038/s41392-023-01557-7. PMID: 37468460; PMCID: PMC10356842.
14. Ananya, A., Holden, K.G., Gu, Z. *et al.* "Just right" combinations of adjuvants with nanoscale carriers activate aged dendritic cells without overt inflammation. *Immun Ageing* 2023; **20**, 10. https://doi.org/10.1186/s12979-023-00332-0
15. Sicard, T., Kassardjian, A., & Julien, J. P. B cell targeting by molecular adjuvants for enhanced immunogenicity. *Expert Review of Vaccines,* 2020; *19*(11), 1023–1039. https://doi.org/10.1080/14760584.2020.1857736
16. Nguyen-Contant P, Sangster MY, Topham DJ. Squalene-Based Influenza Vaccine Adjuvants and Their Impact on the Hemagglutinin-Specific B Cell Response. *Pathogens.* 2021; 10(3):355. https://doi.org/10.3390/pathogens10030355
17. Budroni, S., Buricchi, F., Cavallone, A. *et al.* Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. *npj Vaccines.* 2021; **6**, 78. https://doi.org/10.1038/s41541-021-00337-0
18. Djurisic S, Jakobsen JC, Petersen SB, Kenfelt M, Klingenberg SL, Gluud C. Aluminium adjuvants used in vaccines. Cochrane Database Syst Rev. 2018; 2(7):CD013086. doi: 10.1002/14651858.CD013086. PMCID: PMC6373706.
19. Facciolà A, Visalli G, Laganà A, Di Pietro A. An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. Vaccines (Basel). 2022; 10(5):819. doi: 10.3390/vaccines10050819. PMID: 35632575; PMCID: PMC9147349.

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

20. HogenEsch, H., O'Hagan, D.T. & Fox, C.B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. *npj Vaccines* 2018; **3**, 51. https://doi.org/10.1038/s41541-018-0089-x
21. Lan J, Feng D, He X, Zhang Q, Zhang R. Basic Properties and Development Status of Aluminum Adjuvants Used for Vaccines. *Vaccines*. 2024; 12(10):1187. https://doi.org/10.3390/vaccines12101187
22. Ahmed M, Farris E, Swanson RV, Das S, Yang Y, Martin T, Khader SA. Saponin TQL1055 adjuvant-containing vaccine confers protection upon *Mycobacterium tuberculosis* challenge in mice. Hum Vaccine Immunotherapy. 2024; 20(1):2302070. doi: 10.1080/21645515.2024.2302070. Epub 2024 Jan 8. PMID: 38190806; PMCID: PMC10793695.
23. Parvin N, Joo SW, Mandal TK. Enhancing Vaccine Efficacy and Stability: A Review of the Utilization of Nanoparticles in mRNA Vaccines. Biomolecules. 2024; 14(8):1036. doi: 10.3390/biom14081036. PMID: 39199422; PMCID: PMC11353004.
24. Lin Y, Chen X, Wang K, Liang L, Zhang H. An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer. *Vaccines*. 2024; 12(7):727. https://doi.org/10.3390/vaccines12070727
25. Zhao, T., Cai, Y., Jiang, Y. *et al.* Vaccine adjuvants: mechanisms and platforms. *Sig Transduct Target Ther.*, 2023; **8**, 283. https://doi.org/10.1038/s41392-023-01557-7
26. Cao, LM., Yu, YF., Li, ZZ. *et al.* Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions. *J Nanobiotechnol.*, 2024; **22**, 308. https://doi.org/10.1186/s12951-024-02590-6
27. Petrovsky N. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Saf. 2015; 38(11):1059-74. doi: 10.1007/s40264-015-0350-4. PMID: 26446142; PMCID: PMC4615573.
28. Nanishi E, Dowling DJ, Levy O. Toward precision adjuvants: optimizing science and safety. Curr Opin Pediatr. 2020; 32(1):125-138. doi: 10.1097/MOP.0000000000000868. PMID: 31904601; PMCID: PMC6970548.
29. Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015; 100:190-209. doi: 10.1016/j.phrs.2015.08.003. Epub 2015 Aug 12. PMID: 26275795; PMCID: PMC7129276.
30. Rose NR. The adjuvant effect in infection and autoimmunity. Clin Rev Allergy Immunol. 2008; 34(3):279-82. doi: 10.1007/s12016-007-8049-7. PMID: 18175074.
31. Levast B, Awate S, Babiuk L, Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S. Vaccine Potentiation by Combination Adjuvants. Vaccines (Basel). 2014; 2(2):297-322. doi: 10.3390/vaccines2020297. PMID: 26344621; PMCID: PMC4494260.
32. Stewart E, Triccas JA, Petrovsky N. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. *Microorganisms*. 2019; 7(8):255. https://doi.org/10.3390/microorganisms7080255

CITE AS: Zikayo Amulaga R. (2025). Adjuvants in Infant Immunization: Advances and Challenges in Vaccine Development. Newport International Journal of Research in Medical Sciences, 6(2):1-5
https://doi.org/10.59298/NIJRMS/2025/6.2.15000